These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38971463)

  • 1. Ruxolitinib Plus Basiliximab Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease in Unrelated Cord Blood Transplantation: A Large-Scale Study.
    Wu Y; Sun G; Tang B; Song K; Cheng Y; Tu M; Zhu X
    Transplant Cell Ther; 2024 Sep; 30(9):916.e1-916.e12. PubMed ID: 38971463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.
    Gao Z; Fan Z; Liu Z; Ye X; Zeng Y; Xuan L; Huang F; Lin R; Sun J; Liu Q; Xu N
    Front Immunol; 2024; 15():1408211. PubMed ID: 39021571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
    Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
    Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study.
    Liu SN; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ; Mo XD
    Am J Hematol; 2020 Aug; 95(8):927-936. PubMed ID: 32311156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basiliximab Treatment for Patients With Steroid-Refractory Acute Graft-Versus-Host Disease Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation.
    Jiang XY; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Sun YQ; Mo XD; Huang XJ
    Cell Transplant; 2024; 33():9636897241257568. PubMed ID: 38832653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of basiliximab in the treatment of 87 cases of steroid-refractory or steroid-dependent acute graft-versus-host disease].
    He ZX; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Chen X; Jiang EL; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):120-127. PubMed ID: 35381672
    [No Abstract]   [Full Text] [Related]  

  • 7. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.
    Fu H; Sun X; Lin R; Wang Y; Xuan L; Yao H; Zhang Y; Mo X; Lv M; Zheng F; Kong J; Wang F; Yan C; Han T; Chen H; Chen Y; Tang F; Sun Y; Chen Y; Xu L; Liu K; Zhang X; Liu Q; Huang X; Zhang X
    BMC Med; 2024 Feb; 22(1):85. PubMed ID: 38413930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
    Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
    Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis.
    Mo XD; Hong SD; Zhao YL; Jiang EL; Chen J; Xu Y; Sun ZM; Zhang WJ; Liu QF; Liu DH; Wan DM; Mo WJ; Ren HY; Yang T; Huang H; Zhang X; Wang XN; Song XM; Gao SJ; Wang X; Chen Y; Xu B; Jiang M; Huang XB; Li X; Zhang HY; Wang HT; Wang Z; Niu T; Wang JS; Xia LH; Liu XD; Li F; Zhou F; Lang T; Hu J; Wu SJ; Huang XJ
    Am J Hematol; 2022 Apr; 97(4):458-469. PubMed ID: 35064928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host disease.
    Murray A; Linn SM; Yu B; Novitzky-Basso I; Mattsson J; Kennah M; Elemary M; White J; Lemieux C; Jamani K; Kim DDH
    Bone Marrow Transplant; 2024 Jun; 59(6):759-764. PubMed ID: 38402344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-
    Shen MZ; Li JX; Zhang XH; Xu LP; Wang Y; Liu KY; Huang XJ; Hong SD; Mo XD
    Front Immunol; 2021; 12():749266. PubMed ID: 34621279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients.
    Wei C; Zhang X; Liang D; Yang J; Du J; Yue C; Deng L
    Drug Des Devel Ther; 2021; 15():4875-4883. PubMed ID: 34880598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial.
    Zhao K; Lin R; Fan Z; Chen X; Wang Y; Huang F; Xu N; Zhang X; Zhang X; Xuan L; Wang S; Lin D; Deng L; Nie D; Weng J; Li Y; Zhang X; Li Y; Xiang AP; Liu Q
    J Hematol Oncol; 2022 Mar; 15(1):22. PubMed ID: 35255929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basiliximab as Treatment for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients after Haploidentical Hematopoietic Stem Cell Transplantation.
    Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):351-357. PubMed ID: 31704470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis.
    Abedin S; Rashid N; Schroeder M; Romee R; Nauffal M; Alhaj Moustafa M; Kharfan-Dabaja MA; Palmer J; Hogan W; Hefazi M; Larson S; Holtan S; DeFilipp Z; Jayani R; Dholaria B; Pidala J; Khimani F; Grunwald MR; Butler C; Hamadani M
    Br J Haematol; 2021 Nov; 195(3):429-432. PubMed ID: 34254289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis.
    Denk A; Edinger M; Weber D; Holler E; Fante M; Meedt E; Gunes S; Poeck H; Mittermaier C; Herr W; Wolff D
    Ann Hematol; 2024 Aug; 103(8):3071-3081. PubMed ID: 38916740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
    Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
    Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
    Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V;
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.
    Teshima T; Onishi Y; Kato K; Taniguchi S; Miyamura K; Fukushima K; Kato J; Ishikawa T; Doki N; Nakamae H; Maeda Y; Inamoto Y; Okada M; Maki A; Shimada F; Tajima T; Wroclawska M; Zeiser R; Onizuka M
    Int J Hematol; 2024 Jul; 120(1):106-116. PubMed ID: 38796666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.